Walmart, Home Depot adopt health insurer tactic in drug copay battle
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street falls as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil up almost 2% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Home Depot (HD) Declares $1.03 Quarterly Dividend; 2.3% Yield
November 15, 2018 4:04 PM ESTHome Depot (NYSE: HD) declared a quarterly dividend of $1.03 per share, or $4.12 annualized.
The dividend will be payable on December 13, 2018, to stockholders of record on November 29, 2018, with an ex-dividend date of November 28, 2018.
The annual yield on the dividend is 2.3... More
CVS Health (CVS) Releases Statement on FDA Decision to Restrict Flavored Tobacco Products
November 15, 2018 11:16 AM ESTCVS Health (NYSE: CVS) today announced its support for the U.S. Food and Drug Administration's plans to restrict access to flavored tobacco and e-cigarette products in the retail setting and impose stricter age-verification requirements for online sales. In addition to eliminating the sale of tobacco products in 2014, CVS Health has never sold e-cigarettes or vaping devices in any of its CVS Pharmacy locations.
"We applaud the FDA's decision to restrict access to flavored tobacco and e-cigarette products, which have been expertly marketed and targeted at teens and young adults and... More
Alector Initiates Phase 1 Trial of AL002 for Treatment of Patients with Alzheimer’s Disease
November 15, 2018 7:08 AM ESTAlector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the initiation of a first-in-human Phase 1 trial called the INVOKE study, investigating the companys second product candidate, AL002, for the treatment of patients with Alzheimers disease. AL002 targets a triggering receptor expressed on myeloid cells 2 (TREM2), which was identified using large scale human genomic studies of Alzheimers disease patients. In 2017, Alector entered a global strategic partnership with AbbVie (NYSE: ABBV) that includes the AL002 program.
At Alector, we believe that Alzheimers... More
